From: Pathophysiological classification of chronic rhinosinusitis
Chronic Rhinosinusitis (CRS; n = 100) | |||||
---|---|---|---|---|---|
1st Decision: Polyps | CRS with Nasal Polyps | CRS without Nasal Polyps | N | ||
 | Present: N = 50.5 | Absent: N = 49.4 | 50.5 | ||
2nd Decision: Aspirin sensitivity | Nasal Polyps with Aspirin Sensitivity (NPasa) | Nasal Polyps with Other Features (NPother) | CRS without (s) Nasal Polyps (CRSsNP) | Osteomeatal Complex Disease (OMC) | Â |
 | 17.1 (airways) | 0 | 3.6 (urticaria) | 4.8 (urticaria) | 25.5 |
3rd Decision: Sinus mucosal thickening | 17.1 | 33.3 | 28.3 | 21.2 (normal sinuses) | 78.7 |
4th Decision: FEV1/FVC<70% FEF25%–75%<70% | 12.8 (75%) 15.6 (91%) | 13.7 (41%) 18.3 (55%) | 5.9 (21%) 8.2 (29%) | 3.0 (14%) 9.1 (43%) | 35.4 51.2 |
5th Decision: Peripheral eosinophils >4% Eos. + asthma: a. atopic b. nonatopic c. Eos/no asthma | 11.1 (65%) 3.0 (18%) 8.0 (47%) 0.0 (0%) | 13.1 (39%) 6.9 (21%) 3.0 (9%) 3.0 (9%) | 9.4 (33%) 5.9 (21%) 2.0 (7%) 1.0 (4%) | 4.0 (19%) 0 (0%) 2.0 (9%) 2.0 (9%) | 37.6 15.8 15.0 6.0 |
6th Decision: IgE < 10 IU/ml Low IgE + low IgG1 or IgG3 | 4.9 (29%) 2.4 (14%) | 5.5 (17%) 1.4 (4%) | 12.5 (44%) 9.0 (32%) | 9.5 (45%) 2.1 (10%) | 32.4 14.9 |
7th Decision: Positive allergy skin tests a. seasonal only b. persistent c. negative d. Excess atopy cases per group | 7.5 (44%) 1.0 (6%) 6.5 (38%) 9.6 (56%) -0.3 (-2%) | 23.6 (71%) 1.0 (3%) 22.6 (68%) 9.7 (29%) 7.9 (24%) | 19.2 (68%) 2.0 (7%) 17.3 (61%) 9.1 (32%) 7.1 (25%) | 8.7 (41%) 0 (0%) 8.7 (41%) 12.5 (59%) -2.0 (-9%) | 59.0 4.0 55.1 40.9 12.7 |
Total per Group | 17.1 (100%) | 33.3 (100%) | 28.3 (100%) | 21.2 (100%) | 99.9 |